Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change $ Change
grade F $5.60 -4.44% -0.26
BCRX closed down 4.44 percent on Thursday, February 23, 2017, on 1.12 times normal volume.

Earnings due: Feb 27

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical BCRX trend table...

Date Alert Name Type % Chg
Feb 22 NR7 Range Contraction -4.44%
Feb 21 Fell Below 50 DMA Bearish -8.20%
Feb 21 Expansion Pivot Sell Setup Bearish Swing Setup -8.20%
Feb 17 Stochastic Reached Overbought Other -14.63%
Feb 15 Crossed Above 50 DMA Bullish -9.09%
Feb 10 Bearish Engulfing Bearish -1.06%
Feb 10 180 Bearish Setup Bearish Swing Setup -1.06%
Feb 9 NR7 Range Contraction -6.67%
Feb 7 Doji - Bullish? Reversal -1.23%
Feb 6 Stochastic Reached Oversold Other -0.88%

Older signals for BCRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company’s product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Is BCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 7.56
52 Week Low 1.89
Average Volume 1,047,735
200-Day Moving Average 4.6
50-Day Moving Average 6.19
20-Day Moving Average 6.02
10-Day Moving Average 6.02
Average True Range 0.38
ADX 14.98
+DI 22.18
-DI: 31.13
Chandelier Exit (Long, 3 ATRs) 5.61
Chandelier Exit (Short, 3 ATRs) 6.48
Upper Bollinger Band 6.64
Lower Bollinger Band 5.4
Percent B (%b) 0.16
Bandwidth 0.20598